ABSTRACT
This chapter describes trade name, classification, approved indications for psychological disorders, available dosage forms, storage, and compatibility, usual dosage and administration, relative contraindications, and clinically significant drug interactions of Anileridine. The injectable formulation of anileridine is for intramuscular or subcutaneous injection. Anileridine is a relatively strong, centrally acting, synthetic opiate analgesic. Anileridine is well absorbed after oral ingestion and intramuscular and subcutaneous injection. Prescribe anileridine pharmacotherapy only when required for the symptomatic management of acute moderate to severe pain, and do not unnecessarily prolong pharmacotherapy. The signs and symptoms of anileridine overdosage include severe respiratory depression with circulatory depression and related sequelae. Concurrent anileridine pharmacotherapy with other opiate analgesics, sedative-hypnotics, or other drugs that produce Central Nervous System (CNS) depression may cause additive CNS, respiratory, or circulatory depression. Anileridine pharmacotherapy can further increase intracranial pressure among these patients.
